- Home
- PMVP vs VTGN Comparison
PMVP vs VTGN Comparison
Compare PMVP & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | VTGN |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 122.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMVP | VTGN |
|---|---|---|
| Price | $1.25 | $4.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 262.9K | ★ 1.0M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $721,000.00 |
| Revenue This Year | N/A | $54.26 |
| Revenue Next Year | N/A | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $1.90 |
| 52 Week High | $1.84 | $5.14 |
Technical Indicators
Market Signals| Indicator | PMVP | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 50.22 |
| Support Level | $1.14 | $3.91 |
| Resistance Level | $1.30 | $4.60 |
| Average True Range (ATR) | 0.06 | 0.47 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 39.13 | 50.00 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.